Why the study?
Does rubella vaccine (HPV-77:DE-5) cause joint reactions and induce immunologic response in young, postpuberal females compared to placebo?
Does rubella vaccine (HPV-77:DE-5) cause joint reactions and induce immunologic response in young, postpuberal females compared to placebo?
Rubella vaccination in susceptible postpuberal females is associated with a high rate of seroconversion but carries a significant risk of potentially prolonged joint reactions.
Answers are grounded in this paper and cite their sources.
Caution susceptible postpuberal females about elevated arthritis risk before rubella vaccination; confirms robust immunogenicity while extending safety data to adults.
A controlled double-blind field trial of rubella vaccine (HPV-77:DE-5) was conducted in 150 young, postpuberal females. Arthralgia or arthritis occurred in 39% of the susceptible subjects given vaccine, in 12% of the immune subjects who received vaccine, and in 10% of the placebo recipients. There was no correlation between the occurrence of joint reactions and age (range, 15 to 26 years). One girl had recurrences of joint symptoms for a year after immunization. Seroconversion occurred in 100% of susceptibles but with a mean antibody titer one seventh as high as was observed after natural rubella infection. Subjects with both arthralgia or arthritis and virus excretion developed a significantly higher mean antibody titer than those without either joint reactions or virus excretion. Immune subjects who were given vaccine had neither antibody titer boosts nor virus excretion. The use of rubella vaccine in susceptible postpuberal females entails the risk of joint reactions that may be prolonged.
No takes yet. Share an insight, caveat, or question.
Stephen J. Lerman (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: